Table Of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Inherited Retinal Disease Market: By Disease Type Market Trends, Size, and Future Outlook
- By Disease Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Disease Type Definitions, Technology Landscape
- By Disease Type Market Drivers
- Product Launches
- Technology Launches
- By Disease Type Market Restraints
Chapter 4. Inherited Retinal Disease Market: By Gene Mutation Market Trends, Size, and Future Outlook
- By Gene Mutation Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Gene Mutation Definitions, Technology Landscape
- By Gene Mutation Market Drivers
- Product Launches
- Technology Launches
- By Gene Mutation Market Restraints
Chapter 5. Inherited Retinal Disease Market: By Treatment Type Market Trends, Size, and Future Outlook
- By Treatment Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Treatment Type Definitions, Technology Landscape
- By Treatment Type Market Drivers
- Product Launches
- Technology Launches
- By Treatment Type Market Restraints
Chapter 6. Inherited Retinal Disease Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
Inherited Retinal Disease Market: Competitive Landscape
- Spark Therapeutics (Novartis)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- ProQR Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AGTC
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Nightstar Therapeutics (Biogen)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Horama
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Editas Medicine
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Acucela
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Shire (Takeda)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novelion Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Kubota Vision
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Regenxbio
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GenSight Biologics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Nanoscope Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ocugen
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Allergan (AbbVie)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ionis Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Alkeus Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Gemini Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ophthotech
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Inherited Retinal Disease industry is estimated to be around USD 2.1 billion.
Increasing prevalence, Aging population, Advancements in gene therapies, Improved diagnostics, Growing awareness, Rising healthcare expenditure, Increasing investments in research and development, Expansion of genetic testing services, Development of novel treatment modalities, Increasing adoption of personalized medicine approaches.
High treatment costs and affordability issues, Regulatory challenges and ethical concerns, Limited availability of gene therapies, Complex genetic nature of IRDs, Lack of awareness in certain regions, Challenges in disease diagnosis, Reimbursement issues.
The retinitis pigmentosa segment is the leading component segment in the Inherited Retinal Disease Market due to its high prevalence and ongoing research efforts for effective treatments.
Spark Therapeutics (Novartis), ProQR Therapeutics, AGTC, Nightstar Therapeutics (Biogen), Horama, Sanofi, Editas Medicine, Acucela, Shire (Takeda), Novelion Therapeutics, Kubota Vision, Regenxbio, GenSight Biologics, Nanoscope Therapeutics, Ocugen, Allergan (AbbVie), Ionis Pharmaceuticals, Alkeus Pharmaceuticals, Gemini Therapeutics, Ophthotech.
The global Inherited Retinal Disease Market is projected to grow at a CAGR of 18.2% during the forecast period of 2024-2031, reaching a market size of US$ 8.0 billion by 2031.
Increasing prevalence, Aging population, Advancements in gene therapies, Improved diagnostics, Growing awareness, Rising healthcare expenditure, Increasing investments in research and development, Expansion of genetic testing services.